Compare Alliant Energy Corporation (LNT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Organon & Co. Common Stock — how do they compare? Alliant Energy Corporation trades at $67.51 (market cap $17.36B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Alliant Energy Corporation is far larger — about 4.8× Organon & Co. Common Stock's market cap, and Alliant Energy Corporation pays the higher dividend (3.2%). Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 65 Days and Organon & Co. Common Stock for 0 Days on average.
| LNT | OGN | |
|---|---|---|
Market Cap | $17.36B | $3.62B |
Volume | 1,948,386 | 2,892,999 |
Sector | Utilities | Health |
52-Week High | $78.03 | $13.81 |
52-Week Low | $63.21 | $5.70 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $29.46B | $11.04B |
Dividend Yield | 3.2% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $67.51, up 1.58% with a bullish technical signal despite mixed momentum indicators. The company shows solid fundamentals with Q2 2026 earnings beating expectations at $0.65 per share and maintaining 18.45% net margins. Recent news highlights institutional accumulation and a $13.4 billion capital investment plan through 2029 supporting long-term growth. Analyst consensus remains positive with a $75.17 price target and no sell ratings.
LNT presents a favorable risk-reward profile with strong utility operations, consistent dividend growth, and data center demand driving revenue. Key risks include rising debt levels (48.48% debt-to-asset ratio) and interest rate sensitivity. The stock offers defensive value with upside potential to analyst targets, though investors should monitor execution of the large capex plan and regulatory developments.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
